GEE models showing predictors of discrepancies between prescribed and administered polypharmacy rates
| No look-back | One-week look-back | Two-week look-back | Four-week look-back | |
| OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
| Demographics | ||||
| Male versus female | 1.11 (0.98 to 1.25) | 1.14 (0.97 to 1.34) | 1.16 (0.98 to 1.37) | 1.13 (0.95 to 1.36) |
| Age group (Ref≥90 years old) | ||||
| <80 | 1.39 (1.19 to 1.62) | 1.2 (0.98 to 1.46) | 1.15 (0.93 to 1.41) | 1.12 (0.90 to 1.410 |
| 80–85 | 1.39 (1.20 to 1.60) | 1.25 (1.03 to 1.51) | 1.15 (0.94 to 1.41) | 1.09 (0.88 to 1.35) |
| 86–89 | 1.30 (1.13 to 1.51) | 1.17 (0.97 to 1.43) | 1.11 (0.90 to 1.36) | 1.08 (0.86 to 1.35) |
| Provider A versus provider B | 0.92 (0.82 to 1.04) | 0.95 (0.82 to 1.11) | 0.90 (0.77 to 1.06) | 0.95 (0.79 to 1.14) |
| New versus existing cohort | 1.04 (0.94 to 1.16) | 0.99 (0.86 to 1.14) | 0.97 (0.83 to 1.12) | 1.03 (0.88 to 1.22) |
| Health status | ||||
| Cerebrovascular accident | 1.11 (0.99 to 1.24) | 1.09 (0.94 to 1.27) | 1.11 (0.95 to 1.30) | 1.07 (0.89 to 1.28) |
| Diabetes | 2.63 (2.36 to 2.94) | 2.60 (2.25 to 3.01) | 2.41 (2.07 to 2.81) | 2.11 (1.78 to 2.50) |
| Thyroid | 1.28 (1.10 to 1.50) | 1.14 (0.90 to 1.44) | 1.10 (0.86 to 1.42) | 1.21 (0.93 to 1.58) |
| Chronic respiratory disease | 1.30 (1.15 to 1.46) | 1.19 (1.01 to 1.40) | 1.07 (0.90 to 1.28) | 0.99 (0.81 to 1.20) |
| Neoplasms | 1.04 (0.92 to 1.17) | 1.13 (0.97 to 1.31) | 1.14 (0.98 to 1.33) | 1.16 (0.98 to 1.37) |
| Parkinson’s disease | 1.38 (1.16 to 1.65) | 1.13 (0.89 to 1.45) | 1.12 (0.87 to 1.45) | 1.08 (0.81 to 1.43) |
| Peptic ulcer/gastro-oesophageal reflux disease | 1.24 (1.12 to 1.38) | 1.17 (1.02 to 1.35) | 1.11 (0.96 to 1.29) | 1.04 (0.88 to 1.22) |
| Renal disease | 1.36 (1.20 to 1.53) | 1.32 (1.13 to 1.55) | 1.27 (1.08 to 1.50) | 1.11 (0.92 to 1.33) |
| Dementia | 0.60 (0.54 to 0.67) | 0.68 (0.59 to 0.78) | 0.74 (0.64 to 0.86) | 0.81 (0.69 to 0.95) |
| Osteoporosis | 1.08 (0.96 to 1.21) | 1.17 (1.00 to 1.37) | 1.21 (1.02 to 1.43) | 1.27 (1.06 to 1.52) |
| Arthritis | 1.07 (0.96 to 1.20) | 1.02 (0.88 to 1.18) | 0.99 (0.85 to 1.16) | 0.98 (0.83 to 1.16) |
| Gout | 1.27 (1.08 to 1.49) | 1.23 (0.99 to 1.53) | 1.21 (0.96 to 1.53) | 1.22 (0.94 to 1.59) |
| Fracture | 1.06 (0.95 to 1.19) | 1.04 (0.89 to 1.21) | 1.09 (0.93 to 1.28) | 1.17 (0.99 to 1.39) |
| Hearing impairment | 0.94 (0.831.07) | 0.77 (0.65 to 0.92) | 0.77 (0.64 to 0.92) | 0.75 (0.61 to 0.91) |
| Depression, mood and affective disorders | 1.16 (1.04 to 1.30) | 1.02 (0.88 to 1.18) | 0.97 (0.83 to 1.13) | 0.95 (0.80 to 1.12) |
| Anxiety and stress-related disorders | 1.19 (1.06 to 1.33) | 1.11 (0.95 to 1.3) | 1.07 (0.90 to 1.26) | 1.00 (0.83 to 1.21) |
| Visual impairment | 1.02 (0.89 to 1.16) | 1.09 (0.91 to 1.31) | 1.10 (0.92 to 1.33) | 1.15 (0.94 to 1.42) |
P<0.05 was indicated in bold.
GEE, generalised estimating equations.